Compare Gilead Sciences, Inc. (GILD) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sirius XM Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $133.06 (market cap $163.51B), while Sirius XM Holdings Inc trades at $31.26 (market cap $10.32B). The key difference: Gilead Sciences, Inc. is far larger — about 15.8× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| GILD | SIRI | |
|---|---|---|
Market Cap | $163.51B | $10.32B |
Sector | Health | Media |
52-Week High | $155.80 | $30.75 |
52-Week Low | $108.22 | $19.92 |
Enterprise Value | $178.05B | $19.99B |
Dividend Yield | 2.49% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Sirius XM Holdings (SIRI) trades at $30.39, down 0.91% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 results due July 30. Recent developments include a strategic ad tech partnership with YouTube and potential inclusion in the S&P MidCap 400, driving positive investor sentiment.
The outlook remains positive with analyst consensus at Buy (58%) and $31.17 price target. Strong cash flow generation supports dividends and buybacks, though high debt levels and competitive pressures in media streaming present ongoing risks. Recent return to profitability after 2024's net loss positions SIRI for sustained growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
